Back to Journals » Drug Design, Development and Therapy » Volume 5

Current difficulties and recent advances in bypass therapy for the management of hemophilia with inhibitors: a new and practical formulation of recombinant factor VIIa

Authors Butros L, Boayue K, Mathew P

Published 12 May 2011 Volume 2011:5 Pages 275—282

DOI https://doi.org/10.2147/DDDT.S17722

Review by Single anonymous peer review

Peer reviewer comments 2



Linda Butros, Koh Boayue, Prasad Mathew
The University of New Mexico, Albuquerque, New Mexico, USA

Abstract: Bypassing agents are the mainstay of treatment for patients with hemophilia with high-titer inhibitors. Whereas the availability of these agents has greatly advanced the management of bleeding episodes in this population, timely administration of bypassing agents continues to be hampered by a number of practical limitations, including the need for refrigerated storage of the agent and its reconstitution at room temperature prior to administration, among others. In this review, the importance of early treatment of bleeds and factors that influence this more timely therapeutic approach are highlighted, together with the advantages offered by the use of a new formulation of recombinant activated factor VII that permits improved storage and portability, potentially optimizing timely bypassing agent administration.

Keywords: hemophilia, inhibitors, bleeding, treatment, patients, recombinant factor VIIIa

Creative Commons License © 2011 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.